Global Immunoprotein Diagnostic Testing Market – Industry Trends and Forecast to 2030

Análise e dimensão do mercado de testes de diagnóstico de imunoproteínas

A enorme prevalência de doenças crónicas está a aumentar a procura de testes de diagnóstico de imunoproteínas. De acordo com os registos da OMS, os dados do Observatório Global de Saúde recomendam que cerca de 1,6 milhões, o que resulta em 2,8% do total de mortes, são causadas por diabetes. Os ensaios de quimioluminescência foram desenvolvidos rapidamente em relação aos enormes avanços tecnológicos no diagnóstico de imunoproteínas. Existem diversas tecnologias que estão a auxiliar na deteção rápida de doenças crónicas possuindo ferramentas totalmente automatizadas.

A Data Bridge Market Research analisa que o mercado de testes de diagnóstico de imunoproteínas deverá atingir os 14,58 mil milhões de dólares até 2030, o que equivale a 8,36 mil milhões de dólares em 2022, e deverá passar por um CAGR de 7,2% durante o período de previsão de 2023 a 2030. Além de os insights sobre cenários de mercado, tais como valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research também incluem análise especializada aprofundada, epidemiologia dos doentes, análise de pipeline, análise de preços e enquadramento regulamentar .

Âmbito e segmentação do mercado de testes de diagnóstico de imunoproteínas

Definição de mercado

As imunoproteínas são as proteínas do sangue que desempenham um papel importante no funcionamento do sistema imunitário. Estas proteínas contêm uma actividade imunológica contra substâncias patogénicas, uma vez que apresentam um aumento anormal na concentração sanguínea, actuando assim como um indicador padrão no diagnóstico de doenças durante um estado insalubre. As imunoproteínas formam um sistema corporal completo em células, tecidos ou órgãos que ajudam a equilibrar os efeitos perigosos dos antigénios.

Dinâmica do mercado de testes de diagnóstico de imunoproteínas

Motoristas

• Aumento da incidência de doenças crónicas

A principal razão para o crescimento da procura de serviços de testes de diagnóstico de imunoproteínas é o aumento da incidência e da taxa de incidência de doenças crónicas. De acordo com os registos da OMS, o Observatório Global de Saúde recomenda que quase 1,6 milhões, o que representa cerca de 2,8% do total de mortes, sejam causadas por diabetes. Além disso, só o cancro do pulmão foi o principal responsável em 2012 por causar cerca de 1,6 milhões de mortes, de acordo com as estatísticas do relatório da OMS. A este respeito, o diagnóstico e testes precoces são necessários. Isto impulsiona o crescimento do mercado.

• Aumento da incidência de doenças não transmissíveis e diabetes

De acordo com os registos da OMS, o número de pessoas com diabetes aumentou de 108 milhões em 1980 para 422 milhões em 2014, indicando um enorme aumento da incidência de diabetes. Além disso, de acordo com os dados do Observatório Mundial da Saúde da OMS em 2017, cerca de 70% das mortes globais que levam a 39,5 milhões são causadas por doenças não transmissíveis (DNT), como doenças cardiovasculares, cancros, doenças pulmonares crónicas e diabetes. Assim, isto leva ao aumento destes padrões de teste.

Oportunidades

• Aumento dos testes de diagnóstico

There are several diagnostic tests that are helping in the expansion of the market growth. C-Reactive Protein (CRP) tests is widely used due to the wide product portfolio of major market players. These tests help to identify inflammation by determining the amount of CRP in the patient. It also help in observing the effectiveness of treatment for several infectious diseases and cancer. Furthermore, free light chain diagnostic tests are expected to show major growth during the forecast period. This is because of their ability to help in detection, diagnosis, and monitoring of plasma cell disorders. This testing is beneficial for patients suffering from light chain-only multiple myeloma, oligosecretory myeloma, or nonsecretory myeloma. Thus, all these tests are increasing the market growth.

• Growing Demand of Chemiluminescence assay

Chemiluminescence assay is projected to show the maximum growth during the forecast period because of its high specificity and sensitivity along with ability to identify antigens in human serum and plasma samples. Chemiluminescence assay is often characterized as a major tool for quick diagnosis of numerous diseases and is determined to be more accurate than fluorescence-based detection of labelled probes. Thus, this assay is certainly growing the market growth.

Restraints/Challenges

• High cost of Diagnostic Tests

Different tests are available for testing chronic diseases, cardiovascular and other conditions such as diabetes. But these tests are of much high cost which is not afforded by many patients, especially belonging to the lower economic groups. Thus, it hampers the market growth.

This immunoprotein diagnostic testing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the immunoprotein diagnostic testing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2021, Bio-Rad partnered with Seegene, which is a major market player in multiplex molecular diagnostics, used for the clinical commercialization and huge development of infectious disease diagnostic solutions
• In 2021, Roche collaborated with PathAI, which is a world leader in pathology-based AI-powered technology. The companies collaborated intending to jointly develop an embedded image analysis workflow for different pathologists

Global Immunoprotein Diagnostic Testing Market Scope

The immunoprotein diagnostic testing market is segmented on the basis of type, applications, technology and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• C-Reactive Protein Diagnostic Test
• Complement System Protein Diagnostic Test
• Pre-Albumin Diagnostic Test
• Haptoglobin Diagnostic Test
• Immunoglobulin Diagnostic Test
• Free Light Chain Diagnostic Test
• Others

Applications

• Autoimmune Testing
• Infectious Disease Testing
• Allergy Testing
• Endocrine Testing
• Oncology Testing
• Toxicology Testing
• Others

Technology

• Radioimmunoassay
• Immunoturbidity Assay
• Immunoprotein Electrophoresis
• Enzyme-Linked Immunosorbent Assay
• Others

End-User

• Hospital and Clinics
• Diagnostic Laboratories
• Others

Immunoprotein Diagnostic Testing Regional Analysis/Insights

The immunoprotein diagnostic testing market is analyzed and market size insights and trends are provided by type, applications, technology and end-user as referenced above.

The countries covered in the immunoprotein diagnostic testing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the immunoprotein diagnostic testing market because of the growing incidences of cancer with increasing number of diagnostic instruments and laboratories. Furthermore, high occurrence of cancer among the U.S. population also led to the huge growth of this market. Furthermore, high occurrence of cancer among the U.S. population also led to the growth of this market.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to high frequency of cancer and diabetes among the U.S.  population. Surge in number of government initiatives undertaken in Germany to conduct different tests for people who are suffering from multifactorial and chronic diseases, particularly to detect cancer, lung, diabetes, and cardiovascular disease, is one of the major factors which is responsible for the growth in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The immunoprotein diagnostic testing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for immunoprotein diagnostic testing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the immunoprotein diagnostic testing market. The data is available for historic period 2011-2020.

Competitive Landscape and Global Immunoprotein Diagnostic Testing Market Share Analysis

The immunoprotein diagnostic testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to immunoprotein diagnostic testing market.

Some of the major players operating in the immunoprotein diagnostic testing market are:

• Abbott (U.S.)
• Abcam plc (U.K.)
• Bio-Rad Laboratories, Inc. (U.S.)
• Danaher. (U.S.)
• DiaSorin S.p.A (Italy)
• Enzo Biochem (U.S.)
• Ortho Clinical Diagnostics (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• bioMérieux SA (France)
• Agilent Technologies Inc. (U.S.)
• Enzo Life Sciences, Inc (India)
• Randox Laboratories Ltd (U.K.)
• SERVA Electrophoresis GmbH (Germany)
• Calbiotech (U.S.)
• Eurobio scientific (France)
• Meridian Bioscience, Inc. (U.S.)
• A. Menarini Diagnostics s.r.l (Italy)
• Lilly (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Siemens Healthcare GmbH (Germany)

SKU-56900